论文部分内容阅读
目的探讨星形细胞瘤的增殖活性，及星形细胞瘤的ＤＮＡ倍体特性、细胞周期分布和增殖细胞核抗原标记指数（ＰＣＮＡ－ＬＩ）与病理分级的关系。方法应用流式细胞术（ＦＣＭ）和ＰＣＮＡ免疫染色对５０例星形细胞瘤新鲜组织标本进行ＦＣＭ检测以及ＰＣＮＡ阳性表达的研究。结果（１）ＦＣＭ测定结果示Ⅰ～Ⅳ级星形细胞瘤的异倍体率分别为９．１％、１２．５％、３０．８％和８０％。Ⅰ～Ⅳ级星形细胞瘤的ｓ期比例（ＳＰＦ）分别为１４．１２±４．８９％、１５．９１±１６．６４％、２５．１８±１４．８０％、４１．９２±１７．８４％。（２）正常对照组均未见ＰＣＮＡ阳性表达；Ⅰ～Ⅳ级星形细胞瘤的ＰＣＮＡ－ＬＩ分别为２８．６４±１３．７５％、４５．７５±２２．１４％、６４．３８±１９．１７％和８３．７±６．９９％。结论（１）ＦＣＭ直接评估星形细胞瘤的增殖活性，异倍体和ＳＰＦ有助于病理分级。（２）ＰＣＮＡ－ＬＩ可作为评估增殖活性的良好指标，尤其在Ⅰ级与Ⅱ级判别困难时，ＰＣＮＡ－ＬＩ具有重要价值。
Objective To investigate the proliferative activity of astrocytoma, the DNA ploidy characteristics of astrocytomas, the distribution of cell cycle, and the relationship between PCNA-LI and pathological grade. Methods Flow cytometry (FCM) and PCNA immunostaining were used to detect FCM and positive expression of PCNA in 50 fresh specimens of astrocytoma. Results (1) The results of FCM showed that the aneuploidy rates of grade I-IV astrocytoma were 9.1%, 12.5%, 30.8%, and 80%, respectively. The s phase ratio (SPF) of grade I-IV astrocytomas was 14.12±4.89%, 15.91±16.64%, 25.18±14.80%, and 41.92±17, respectively. 84%. (2) No PCNA expression was observed in the normal control group; the PCNA-LI of grade I-IV astrocytoma was 28.64±13.75%, 45.75±22.14%, and 64.38±19, respectively. .17% and 83.7±6.99%. Conclusions (1) FCM directly evaluates the proliferative activity of astrocytomas, and aneuploidy and SPF contribute to pathological grade. (2) PCNA-LI can be used as a good indicator to evaluate the proliferative activity. PCA-LI is of great value especially when it is difficult to distinguish grade I and grade II.